Vical Inc. will have to refocus its development efforts once again, with the mid-stage trial failure of its genital herpes therapeutic vaccine VCL-HB01. The company is ceasing development of the candidate and will put that capital toward development of its novel antifungal agent.
The herpes simplex virus (HSV)-2 vaccine candidate, developed with the company's proprietary Vaxfectin adjuvant, did not meet the primary endpoint...